Trulicity is my favorite GLP-1 receptor agonist on the market. The device is by far the easiest to use and titrate doses. It has the same A1c lowering ability as the once daily Victoza (AWARD-6 trial), and although Ozempic showed statistically better A1c lowering than Trulicity, they weren't very different clinically. Trulicity also showed some of the best CV benefit in the REWIND trial. Two-thirds of the patients in the study had no history of ASCVD and low CV risk. Most recently, the results of the AWARD-11 trial was followed by the approval of two new doses of Trulicity gaining FDA approval (3 mg and 4.5 mg)
